Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice

By afschroeder • December 16, 2025

Esposito AJ, Selvan KC, Richardson C, Khanna D, Bemiss BC, Bernstein EJ, Chung JH, Cox CW, Dematte JE, Denton CP, Distler O, Hinchcliff ME, Smith V, Strek ME, Varga J, Hoffmann-Vold AM, Volkmann ER. Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice. Chest. 2025 Dec 13:S0012-3692(25)05842-8. doi: 10.1016/j.chest.2025.11.047. Epub ahead of print. PMID: 41397518.

Tags: guidelines, interstitial lung disease, Publications, Rheumatology, screening, systemic sclerosis, Treatment

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

Disease-modifying effects of iron deficiency in mouse models of chronic renal failure

Zhang M, Lundin A, Jung G, Olivera JD, Sangkhae V, Sharma S, Ganz T, Nemeth E, Hanudel MR, Czaya B. Disease-modifying effects of iron deficiency[...]

Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)

Ioannou GN, Taddei TH, Planeta BM, Huang GD, Weiss NS, Morgan TR, Dominitz JA, Abou-Alfa GK, Bashir MR, Beheshti MV, Singal AG, Moylan CA, Boland[...]